Clinical trials: Muscle Disorders
Carcinoma of Urinary Bladder, Invasive
Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer
The purpose of this study is to evaluate the safety of intravesical instillation of TC-3 Hydrogel disposable device for retention of mitomycin C chemotherapeutic drug in the urinary bladder.
- Trial name
- NCT01648010
- Testing
- TC-3 gel, TC-3 gel mixed with Mitomycin C (MMC)
- Where
- 3 sites in Israel
- Volunteers
- 7 people
- Sponsor
- UroGen Pharma Ltd.
Cachexia, Non-Small-Cell Lung Cancer
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
- Conditions
- Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT04299048
- Testing
- PF-06946860
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pfizer
Fibrodysplasia Ossificans Progressiva, FOP
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP.
- Trial name
- OPTIMA-2 (NCT07559513)
- Testing
- garetosmab
- Volunteers
- 18 people
- Sponsor
- Regeneron Pharmaceuticals
Compartment Syndromes
SWISS_CLEARANCE - Compartment Compressibility Monitoring Using CPM#1
Compartment syndrome is a very serious musculoskeletal disorder, which can lead to potentially devastating consequences, such as limb amputation and life- threatening conditions.
- Trial name
- NCT05483946
- Testing
- Measurement of compartment compressibility
- Where
- Switzerland
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Compremium AG
Fibromyalgia
Treatment of Fibromyalgia With the FibroNova Neuromodulation Device
Fibromyalgia (FM) is a chronic disorder that affects the musculoskeletal system, causing widespread pain, tenderness, and fatigue. It is estimated to affect 1-5% of the population.
- Trial name
- NCT06271746
- Testing
- FibroNova (Active mode)
- Where
- 4 sites in United States, Israel
- Volunteers
- 170 people
- Sponsor
- Theranica
Muscle Spasticity
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)
The purpose of this study is to evaluate the safety and pharmacodynamic of CORETOX® in the treatment of post-stroke upper limb spasticity
- Trial name
- NCT05164003
- Testing
- CORETOX®, BOTOX®
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Medy-Tox
Polymyositis, Dermatomyositis
A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients…
- Trial name
- PRESIDIO (NCT04033926)
- Testing
- KZR-616
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 25 people
- Sponsor
- Kezar Life Sciences, Inc.
Schizophrenia, Bipolar I Disorder
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
The purpose of this trial is to determine the safety and tolerability of multiple-dose administrations of aripiprazole, to establish the similarity of aripiprazole concentrations on the last day of the dosing interval following…
- Trial name
- NCT04030143
- Testing
- Aripiprazole
- Where
- 19 sites in United States
- Volunteers
- 266 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Temporomandibular Disorders
Treatment Outcomes for Temporomandibular Disorders (TMD) Via the Clayton Intra-aural Device (CID) Clinical Trial
The purpose of this study is to characterize the safety profile and assess the effectiveness of the CID in treating subjects with temporomandibular disorders (TMDs).
- Trial name
- NCT00815776
- Testing
- Clayton Intra-aural Device (CID), Mouth Splint, Exercise Group
- Where
- Mexico
- Volunteers
- 152 people
- Sponsor
- Ascentia Health, Inc.
Non-Muscle Invasive Bladder Cancer (NMIBC)
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
A Phase Ib, open label, non randomized study to measure the safety and PK characteristics of APL-1202 at steady-state in adult male and female BCG resistant NMIBC patients when it is administered alone and concurrently with BCG.
- Trial name
- NMIBC (NCT03672240)
- Testing
- APL-1202
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Asieris Pharmaceutical Technologies Co., Ltd.
Tendinopathy
Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy
This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease.
- Trial name
- NCT03344640
- Testing
- secukinumab
- Where
- 12 sites in United States, Czechia and 3 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Inflammatory Myopathies, Inflammatory Myopathies
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with Moderate-Severe Idiopathic Inflammatory Myopathies who have failed prior therapies.
- Trial name
- NCT06524687
- Testing
- Imvotamab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- IGM Biosciences, Inc.
NMIBC
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus…
- Trial name
- NCT06800963
- Testing
- Intravesical Recombinant Mycobacterium (rMBCG)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Dermatomyositis
A Study In Adults With Moderate To Severe Dermatomyositis
A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis
- Trial name
- NCT03181893
- Testing
- PF-06823859 low, PF-06823859 high
- Where
- 41 sites in United States, Germany and 3 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Myofascial Pain Syndromes
EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes
Study objective: To demonstrate, in patients with myofascial pain syndrome in cervical region, the degree of efficacy of thiocolchicoside ointment administered to trigger point regions compared with the trigger point injection.
- Trial name
- NCT00272532
- Testing
- Thiocolchicoside
- Where
- Turkey (Türkiye)
- Volunteers
- 65 people
- Sponsor
- Sanofi
Pigmented Villonodular Synovitis, TGCT
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
AMB-051-07 is an open-label, adaptive, dose-ranging study with long-term extension in adults with tenosynovial giant cell tumor
- Conditions
- Pigmented Villonodular Synovitis, TGCT, Tenosynovial Giant Cell Tumor
- Trial name
- NCT05349643
- Testing
- AMB-05X
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- AmMax Bio, Inc.
Muscular Atrophy, Spinal
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
In this study, researchers will learn more about the safety and effects of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have already been treated with…
- Trial name
- STELLAR-2 (NCT07444450)
- Testing
- Salanersen
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Biogen
Non-muscle Invasive Bladder Cancer
Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
To evaluate the clinical efficacy (median event-free survival) of APL-1202 in combination with Epirubicin hydrochloride versus Epirubicin hydrochloride alone in intermediate and high-risk chemo-refractory non-muscle invasive…
- Trial name
- ACCRUE (NCT04490993)
- Testing
- APL-1202 in combination with Epirubicin
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Facioscapulohumeral Muscular Dystrophy
Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies.
- Trial name
- NCT02531217
- Testing
- ATYR1940
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 9 people
- Sponsor
- aTyr Pharma, Inc.
Spasticity
Continuous Intrathecal Baclofen Infusion for Chronic Spasticity
The purpose of this clinical investigation is to demonstrate product performance of the Prometra Programmable Pump System in the delivery of intrathecal Lioresal® (baclofen) for the management of severe spasticity.
- Trial name
- CIBI (NCT01051128)
- Testing
- Prometra Programmable Implantable Pump System
- Sponsor
- Flowonix Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.